TROPONÍN A AKÚTNY KORONÁRNY SYNDRÓM. Vasil Hricak, MD, PhD, FESC.
|
|
- Virgil Freeman
- 6 years ago
- Views:
Transcription
1 TROPONÍN A AKÚTNY KORONÁRNY SYNDRÓM Suspektný akútny koronárny syndróm Čo je nové TRAPID-AMI Odporúčania EKS 2015 Vasil Hricak, MD, PhD, FESC. Professor of Internal Medicine (Cardiology) National Heart Institute Departement of Acute Cardiac Care Bratislava, Slovakia
2 Táto prezentácia/prednáška bola podporená spoločnosťou Roche Slovensko, s.r.o. Spoločnosť Roche Slovensko, s.r.o. však nijako neovplyvňovala obsah, rozsah a ani formulácie textu tejto prezentácie
3 TROPONÍN A AKÚTNY KORONÁRNY SYNDRÓM Motto prednášky: Stratifikácia rizika u pacientov so suspektným akútnym koronárnym syndrómom (AKS) je dôležitá z hľadiska rozhodovania o hospitalizácii a intenzite liečby My advice is to never do tomorrow what you can do today. Procrastination is the thief of time. Charles Dickens (Shetches of young men)...odkladanie môže byť zlodej života a prežitia. V.H.
4 Klinická situácia kedy kardiomarkery zdržujú správny liečebný manažment (AKS-STEMI) Studenčan, Hricák, Kovář a spol. Cardiol Lett 2013
5 TROPONÍN A AKÚTNY KORONÁRNY SYNDRÓM Čo je známe 1. U pts s AKS je pravdepodobnosť predčasného úmrtia v prípade abnormálnej koncentrácie srdcového (c) troponínu zvýšená 3 5x Heidenreich et al. JACC Prospektívne štúdie zaoberajúce sa rozbormi troponínu u AKS dokázali, že diagnostická presnosť hodnôt c-troponínu T a I je porovnateľná, ak nie lepšia, s hodnotami CK-MB a zároveň predurčuje skoré i dlhodobé riziko nežiaducich kardiálnych príhod. BIOMACS Study Group CAD 1995, Polanczyk et al JACC 1998, Gerhardt et al. Clin Chem 1991, Johnson et al JAMA 1999, Hamm et al. NEJM 1997, 3. Problémom dg i patofyziologickým ostáva skutočnosť zvýšených hladín troponínov u pts bez AKS (dif.dg) všeobecne elevácia troponínov indikuje srdcové poškodenie, ale nehovorí o príčine poškodenia (tab. trop bez AKS) 4. Stanovenie hs-ctroponínu T, I, umožňuje detegovať už minimálne poškodenie myokardu, ale tiež sťažuje interpretáciu klinického stavu 5. Doteraz pre dg: dynamika troponínov alebo násobky (5x,10x) v časových intervaloch 0h -6-12h, novšie 0h -3h. 6. Nezabúdať vždy v kontexte zodpovedného vyšetrenia hrudnej bolesti a ekg záznamu
6 V súčasnosti všetky známe príčiny zvýšených a vysokých hladín ctroponínov Troponin workgroup, Arch Cardiovasc Dis 2015
7 Zvýšené hodnoty troponínov mimo AKS - IM I. typu NSTE-ACS, ESC 2015
8 Akútna hrudná bolesť- dg. algoritmus Twerenbold et al. EHJ 2012
9 Akútna hrudná bolesť- dg. algoritmus - 2 problémy Twerenbold et al. EHJ 2012
10 TROPONÍN A AKÚTNY KORONÁRNY SYNDRÓM Čo by sme chceli v najkratšom čase pri podozrení na akútny koronárny syndróm (hrudná bolesť) 1. Čo najskôr potvrdiť alebo vylúčiť dg akútneho infarktu myokardu (AIM) a to čo najistejšie Prečo? Centrálne urgentné príjmy - ideálne už prednemocnične rozhodnutie o hospitalizácii Rozhodnutie o agresivite liečby napr. skoré podanie antitrombotickej liečby (AA+ANK th) Skorá a neskorá prognóza Ekonomický benefit
11 TROPONÍN A AKÚTNY KORONÁRNY SYNDRÓM Otázky 1. Je možné určiť a validovať 1-hodinový algoritmus s absolútnou zmenou pre hs-ctrop s dostatočnou senzitívnosťou, špecifickosťou a N a PPH? 2. Aká má byť špefická cut-off hodnota pre hs-ctrop, ktorá dovolí zodpovedne vylúčiť ( rule-out ) alebo potvrdiť ( rule-in ) AIM behom 1 hodiny (1h)? 3. Koľko pts by mohlo byt rule-out po 1. hodine s vyšetrením hs-ctrop: 0h-1h? 4. Koľko pts by bolo rule-in po 1. hodine s vyšetrením hs-ctrop: 0h-1h? 5. Komparácia algoritmov 0h-3h vs 0h-1h? 6. Ktorý hs-ctroponín T, I? 7. 2-hodinový algoritmus hs-ctrop + ekg prinesie viac informácií v rámci skupiny pts klasifikovaných na pozorovanie ( šedá zóna )?? Rule-in = potvrdený AIM, rule-out = vylúčený AIM
12 TROPONÍN a AKÚTNY KORONÁRNY SYNDRÓM Nedávny vývoj odpovede (vyberám) - pokračovanie 1. r x Univerz dg AIM : dynamika c-troponínu (0h-6-12h) s aspoň jednou hodnotou nad 99 percentil kontrolnej skupiny pri meracom koeficiente 10 % + 1 charakteristicky znak pre IM (symptóm ischémie, ekg-zmeny, zobrazovacie metodiky) (Thygesen et al. JACC 2007) 2. r Study group on Biomarkers in Cardiology of the ESC WG ACC: ako v bode 1. + odporúčanie - ak prvá vzorka ctrop negatívna, 2. odber o 6-12h (niekedy 3. odber o 12-24h. (Thygesen et al EHJ 2010) 3. r odporúčania ESC pre ASC-NSTE: zmienka hs-ctrop: 0h-3h. (Hamm et al. EHJ 2011) 4. r APACE štúdia hs-ctropo T a hs-ctropo I ultra 0h -1h a 2h: porovnanie absolútnych zmien troponínov vs relatívnych: absolútne zmeny troponínov majú signifikantne vyšší prínos pre dg AIM ako relatívne zmeny a lepšie odlíšia AIM od iných príčin zvýšenia c-troponínov (abs.zmena pre hs-ct-t 0,007ug/l. (Reichlin et al, Circulation 2011)
13 TROPONIN A AKÚTNY KORONÁRNY SYNDRÓM Nedávny vývoj odpovede (vyberám) 5. r štúdie ADAPT, APACE (Cullen et al. JACC2013), iné 6. r ESC kongres TRAPID-AMI (Mueller C, ESC kongres Barcelona 2014) 7. r odporúčania AHA/ACC pre AKS-NSTE: troponint alebo I. 0h 3-6h (Amsterdam E et al. Circulation 2014) 8. r validácia 0h-1h pre abs zmenu hs-ctrop: akceleruje diagnostiku a manažment pts so suspektným AIM s rule-out 3 zo 4 pacientov (Reichlin et al CMAJ 2015) 9. r validácia s tým istým pozitívnym záverom pre rule-out a rule-in pre hs-ctrop I (Gimenez et al. Am J Med 2015)
14 TROPONIN A AKÚTNY KORONÁRNY SYNDRÓM Vývoj odpovede (pokračovanie) a čo je nové 10. r ESC kongres: TRAPID AMI potvrdená APACE št. a predchádzajúce štúdie (Mueller C et al. ESC kongres Londýn 2015) Dopad pre prax odporúčania EKS prevzali 11. r Odporúčania EKS pre dg a manažment AKS NSTE (Roffi, Patrono et al. EHJ 2015). 1x odporúčanie aj pre hs-ctrop 0h 1h (absolútne zmeny) pre potvrdenie ( rule-in ) alebo vylúčenie ( rule-out ) AIM u pacientov s podozrením na AKS-IM (tam kde biochemické laboratóriá majú možnosť a sú definované resp. odporúčané analytické testy a jednotlivé absolútne zmeny pre jednotlivé skupiny pacientov s podozrením na AKS-AIM) Doterajší algoritmus troponínov 0h 3h ostáva v odporúčaniach 2015 Cave: ak je pacient prijatý v 1. hodine hrudnej bolesti, 2. odber c-troponínu má byť urobený o 3 hod (ESC 2015)
15
16 TRAPID-AMI: prospektívne zhodnotenie (validácia) hs-ctroponin T 0h 1h algoritmus z APACE št. (APACE prospektívna observačná št validovaná 2015, retrospektívne získané hodnoty) HOT LINE Session, Barcelona ESC 2014 TRAPID - AIM: (hst-t absolútne hodnoty a ich zmena ako v APACE št.-pozri vyššie) 1.NPH 99,1 % a senzitivita pre AIM 96,7 % pri vylúčení AIM (u 7 pts falošne neg výsledok = mali AIM) 2. PPH 77,2 % a špecifickosť pre AIM 96,1 % pri potvrdení AIM 3. Šedá zóna (observácia pts ekg monitor, iné) 22.5 % HOT LINE Ses, London, ESC 2015 publ. 2016
17 Susp. AKS a hs-ctroponín T alebo I: dg. algoritmus 0h 1h ED ED: urgentné príjmy AKS: akútny koronárny syndróm h: hodina, NSTE-ACS, ESC 2015
18
19 Susp. AKS a hs-ctroponín I: mortalita chorých s potvrdeným a vylúčeným AIM a chorých ponechaných na pozorovanie Gimenez et al. Am J Med 2015
20 Susp. AKS a hs-ctroponín T: mortalita chorých s potvrdeným a vylúčeným AIM a chorých ponechaných na pozorovanie Reichlin et al. CMAJ 2015
21 ODKAZ štúdií APACE a TRAPID-AMI (hs-troponín-t) 1. Algoritmus stanovenia hs-t-t : 0h/1h u pts s hrudnou bolesťou (najlepšie do 6 h) vylúči alebo potvrdí AIM NSTEMI u 78 % chorých (60 % vlúčenie AIM). Prednosť má vždy ekg- záznam, ktorý potvrdí alebo vylúči AKS STEMI!! 2. 0h/1h: pozitívna prediktívna hodnota=75-80 %, špecifickosť 96 % pre potvrdenie AIM % chorých vyžaduje ďalšie sledovanie ( šedá zóna ) (zvýšené K-V riziko) 4. hs-tnt je vysoko senzitívny marker, kvantitatívny marker pre poškodenie kardiomyocytov z rôznych príčin. Čím Î hs-tnt, tým vyššia pravdepodobnosť AIM a opačne! 5. Každá biomarkerová informácia má byť vždy integrovaná do klinického komplexného zhodnotenia stavu chorého (napr. aj v 0h nedetegovateľná hodnota hs-t-t vyžaduje klinické zhodnotenie, hst-t má vysokú negatívnu prediktívnu hodnotu) Doterajší algoritmus troponínov 0h 3h ostáva v odporúčaniach 2015 Cave: ak je pacient prijatý v 1. hodine hrudnej bolesti, 2. odber hs-troponinu má byť urobený o 3 hod (ESC 2015)
22 Štandardný troponín 0h /6-12h Troponín a suspektný AKS jednotlivé vyšetrovacie postupy s cieľom zlepšenia čo najskôr vylúčiť alebo potvrdiť akútny infarkt myokardu (AIM) = benefit pre pacienta = rozhodovanie o komplexnom manažmente. hstroponín 0h/3h hs Troponín T 0h/1h 78 % pts vyriešených
23 ACC/AHA 2014 odporúčania pre AKS-NSTE: absolútne zmeny sú lepšie v rule-in / rule-out AIM ako relatívne zmeny
24 Zvýšenie troponínu urgentný príjem a 30- dňová mortalita u chorých bez AKS Chron. zvýš. pri asymptom. AoS...rizikový prognostiky faktor... (2015)
25 Suspektný AKS: hs-ctroponín: 0h-1h Hudba súčasnosti pri podozrení na AIM s EBM: I B
26
27 Susp. AKS a hs-ctroponín: algoritmus 0h 3h ED NSTE - ACS, ESC 2015
28
BioRemarkable Symposium
BACC BioRemarkable Symposium Acute Myocardial infarction Stefan Blankenberg University Heart Center Hamburg London, September 7th, 2017 Universitätsklinikum Hamburg-Eppendorf Third Universal-Definition
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationBertil Lindahl Akademiska sjukhuset Uppsala
Bertil Lindahl Akademiska sjukhuset Uppsala Kriterier för akut hjärtinfarkt Bevis på myokardskada/nekros: Konstaterad höjning och/eller sänkning av biomarkörer (företrädesvis troponin) med minst ett värde
More informationDiagnostika a liečba relabovaného a refraktérneho DLBCL
Diagnostika a liečba relabovaného a refraktérneho DLBCL Miriam Ladická Národný onkologický ústav Vysoká účinnosť Akceptovateľná Liečba ochorenia toxicita Minimálne neskoré NÚ cca 1/3 pacientov s DLBCL
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationBetter, higher, lower, faster: increasingly rapid clinical decision making using high-sensitivity cardiac troponin assays
Editorial Page 1 of 5 Better, higher, lower, faster: increasingly rapid clinical decision making using high-sensitivity cardiac troponin assays Noreen van der Linden, Alexander S. Streng, Will K. W. H.
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationHit the road Jack! W. FRANK PEACOCK, MD, FACEP, FACC
Hit the road Jack! W. FRANK PEACOCK, MD, FACEP, FACC Visits 130,000,000 annually 10.4 M chest pain (8.0%) 4.1 M sent home non-cardiac 6.24 M suspected or actual cardiac 50,000 MIs 3.1 M non-cardiac (50%)
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Speaker: Date: Location: Troponin State of the Art: Past, Present and Future Yader Sandoval, MD Cardiovascular Disease Fellow Minneapolis Heart Institute at Abbott
More informationCongreso Nacional del Laboratorio Clínico 2016
Can biomarkers help us make a better use of cardiac imaging for myocardial ischaemia rule-out in the Emergency Department? Alessandro Sionis Director Acute and Intensive Cardiac Care Unit Hospital de la
More informationAkútne koronárne syndrómy
Braunwald E et al. J Am Coll Cardiol 2000;36:970 1062. Akútne koronárne syndrómy Akútny koronárny syndróm Bez elevácie ST segm. Elevácia ST segm. IM bez elevácie ST Nestabilná AP Infarkt myokardu bez Q
More informationHigh Sensitivity Troponin Improves Management. But Not Yet
High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationRapid rule out of acute myocardial infarction: novel biomarker-based strategies
653229ACC0010.1177/2048872616653229European Heart Journal: Acute Cardiovascular CareMueller et al. research-article2016 Original scientific paper Rapid rule out of acute myocardial infarction: novel biomarker-based
More informationSympózium laboratórnej diagnostiky Trenčín,
Sympózium laboratórnej diagnostiky Trenčín, 29.11.-30.11.2016 The value of in vitro diagnostics Improving people s health The value of in vitro diagnostics Improving people s health Disease prevention
More information7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay
Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationPost-Procedural Myocardial Injury or Infarction
Post-Procedural Myocardial Injury or Infarction Hugo A Katus MD & Evangelos Giannitsis MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Conflict of Interest:
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationDoes serial troponin measurement help identify acute ischemia/ischemic events?
Does serial troponin measurement help identify acute ischemia/ischemic events? Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine and Laboratory Medicine & Pathology
More informationInternational Journal of Emergency Medicine
Ruangsomboon et al. International Journal of Emergency Medicine (2018) 11:43 https://doi.org/10.1186/s12245-018-0204-9 International Journal of Emergency Medicine ORIGINAL RESEARCH The feasibility of the
More informationLow Risk Chest Pain. Objectives. Disclosure. Case 1. Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School of Medicine
Disclosure Low Risk Chest Pain No Financial Relationships to Disclose No significant investments or savings Unlimited Expenses Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School
More informationNové znenie informácií o lieku výňatky z odporúčaní výboru PRAC týkajúcich sa signálov
25 January 2018 EMA/PRAC/35594/2018 Corr 1 Pharmacovigilance Risk Assessment Committee (PRAC) Nové znenie informácií o lieku výňatky z odporúčaní výboru PRAC týkajúcich sa signálov Prijaté na zasadnutí
More informationImpact of Troponin Performance on Patient Care
Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable
More information9/18/2017. Disclosures. Cardiac Troponin: ER Utilization and the Next Generation
Disclosures Cardiac Troponin: ER Utilization and the Next Generation Joshua Soldo is an employee of Roche Diagnostics within the division of Medical Scientific Affairs. Data presented is intended for purely
More informationTroponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives
Objectives Low Risk Chest Pain Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School of Medicine Improve speed and accuracy in assessing patients with possible ACS! Avoid pitfalls
More informationHow to manage ACS patients with Comorbidities? Patients with Renal Failure
How to manage ACS patients with Comorbidities? Patients with Renal Failure François Schiele, MD, PhD Department of Cardiology, University Hospital Jean Minjoz, Besançon, France. Potential conflicts of
More informationPredanestetické vyšetrenie kardiaka pre nekardiálnu operáciu Štefan Trenkler
Predanestetické vyšetrenie kardiaka pre nekardiálnu operáciu Štefan Trenkler I. klinika AIM UPJŠ LF Košice CEEA Košice 2016 Program 1. Úvod 2. MICA incidencia, mechanizmus 3. Odporúčania pre nekardiálnu
More informationTYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016
TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding
More informationhs-c Tn I high sensitivity troponin I <17 min
hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes
More informationAcute Coronary Syndromes
High-sensitivity Troponins Difficult Friends in Acute Coronary Syndromes Roland Klingenberg, Christian M Matter, 2 Christophe Wyss, Danielle Hof, Arnold von Eckardstein and Thomas F Lüscher 6. Clinical
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More informationSrdcové zlyhávanie v roku 2016 novinky v odporúčaniach, súčasný stav, trendy
163 Srdcové zlyhávanie v roku 2016 novinky v odporúčaniach, súčasný stav, trendy Srdcové zlyhávanie 2016 (HFA/ESC) a 3. svetový kongres o akútnom srdcovom zlyhaní, Florencia, Taliansko, 21. 24. mája 2016
More information10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More information12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2
Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial
More informationOdporúčania pre diagnostiku a liečbu akútnych koronárnych syndrómov bez elevácie segmentu ST
ODPORÚČANIA * GUIDELINES Odporúčania pre diagnostiku a liečbu akútnych koronárnych syndrómov bez elevácie segmentu ST The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationConference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction: Diagnostic Implications
Conference Papers in Medicine, Article ID 583175, 5 pages http://dx.doi.org/10.1155/2013/583175 Conference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction:
More informationPrehľad. III. Riadená hypotermia (RH) I. Hypoxia ischémia (HI) II. Patofyziológia HI
Prehľad I. Hypoxia ischémia (HI) II. Patofyziológia HI III. Riadená hypotermia (RH) 1. účinky a metódy 2. metaanalýzy 3. podmienky a prístroje 4. indikácie 5. aeeg 6. kontraindikácie a prerušenie 7. PRINCÍPY
More informationCase study #1 Evolving Concepts in Non-ST Elevation ACS (NSTE-ACS)
Case study #1 Evolving Concepts in Non-ST Elevation ACS (NSTE-ACS) Fernando Bátiz MD PGY-5 cardiology fellow Hospital Español Fernando Bátiz fernando_batiz@me.com Sex: Female Race: Caucasian Age: 79 years
More informationDobutamínová zá a ová echokardiografia vs SPECT pri diagnostikovaní ischemickej choroby srdca
Původní práce Dobutamínová zá a ová echokardiografia vs SPECT pri diagnostikovaní ischemickej choroby srdca G. Valočik 1, I. Majerčák 1, P. Mitro 1, V. Tóthová 2, I. Marin 2 1 III. interná klinika Lekárskej
More informationObservation Medicine ECG Instructor Workshop session 2 Serial 12 Lead ECG Interpretation
American College of Cardiology 20 th Congress 2017 Observation Medicine ECG Instructor Workshop session 2 Serial 12 Lead ECG Interpretation Part 1 By: Wayne W Ruppert, CVT, CCCC, NREMT-P This curriculum
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationNew diagnostic markers for acute coronary syndromes
New diagnostic markers for acute coronary syndromes - Nye diagnostiske markørerer for akutt iskemisk hjertesykdom Bertil Lindahl, Professor Cardiology, Uppsala University and Uppsala Clinical Research
More informationManagement of cardiovascular disease - coronary interventions -
Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationEarly Rule-Out and Rule-In Strategies for Myocardial Infarction
Papers in Press. Published October 10, 2016 as doi:10.1373/clinchem.2016.254730 The latest version is at http://hwmaint.clinchem.aaccjnls.org/cgi/doi/10.1373/clinchem.2016.254730 Clinical Chemistry 63:1
More informationTable. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.
Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th
More informationChallanges in evaluation of coronary artery disease in patients with diabetes
Challanges in evaluation of coronary artery disease in patients with diabetes Branko Beleslin, MD, PhD, FESC, FACC Cardiology Clinic, Clinical centre of Serbia Medical faculty, University of Belgrade Scope
More informationDiagnostic algorithms for acute coronary syndrome is one better than another?
Review Article Page 1 of 6 Diagnostic algorithms for acute coronary syndrome is one better than another? Gianfranco Cervellin 1, Camilla Mattiuzzi 2, Chiara Bovo 3, Giuseppe Lippi 4 1 Emergency Department,
More informationConfidence and tolerance intervals a tool for biomedical data analysis aimed at clear evidence
PREHĽADNÉ ČLÁNKY * REVIEW ARTICLES Confidence and tolerance intervals a tool for biomedical data analysis aimed at clear evidence MIROSLAV MIKULECKY Bratislava, Slovak republic MIKULECKY M. Confidence
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More informationIFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid 1 CREATED By the EB in 2011, following to the Committee on Standardization of Cardiac
More informationNew universal definition of myocardial infarction
New universal definition of myocardial infarction L. K. Michalis, ΜRCP, FESC Professor of Cardiology, University of Ioannina Changing Criteria for definition of MI Primarily clinical & ECG approach First
More informationFifty shades of Troponin. Dr Liam Penny The Queens Hotel, Cheltenham 4 th October 2012
Fifty shades of Troponin Dr Liam Penny The Queens Hotel, Cheltenham 4 th October 2012 Plaque-fissure and intracoronary thrombus Courtesy Prof. MJ Davies Acute Coronary Syndromes Plaque-fissure and intracoronary
More informationRapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com
More informationManagement of patients with Acute Coronary Syndromes
Original article * Originálny článok Cardiology Lett. 2017;26(3):125 137 Manažment akútnych koronárnych syndrómov na Slovensku v roku 2015. Aktuálne analýzy registra SLOVAKS Studenčan M 1, Hricák V 2,
More information9/11/2017. Hit the road Jack! A review of ADPs (Accelerated Diagnostic Protocols) 2017 COI Disclosures: W. Frank Peacock, MD, FACEP,FACC.
Hit the road Jack! A review of ADPs (Accelerated Diagnostic Protocols) 30 minutes W. FRANK PEACOCK, MD, FACEP, FACC 2017 COI Disclosures: W. Frank Peacock, MD, FACEP,FACC Research Grants: Abbott, Janssen,
More informationAntithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?
Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients
More informationEarly treatment with high-potency statins in patients with acute coronary syndrome an example of personalized medicine
Editorial Early treatment with high-potency statins in patients with acute coronary syndrome an example of personalized medicine Emanuel Harari, Alon Eisen Cardiology Department, Rabin Medical Center,
More informationDocument Version Publisher s PDF, also known as Version of Record (includes final page, issue and volume numbers)
Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.H. Published
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None Controversies on marathon and beyond: Elevated biomarkers as a proof of cardiac damage: Contra Jürgen Scharhag, FACSM, FESC Internal Medicine III: Cardiology, Angiology
More informationHow will new high sensitive troponins affect the criteria?
How will new high sensitive troponins affect the criteria? Hugo A Katus MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Even more sensitive: The new
More informationKardiotoxicita antracyklínovej lieèby vo svetle nových biochemických diagnostických mo ností
Přehledný referát Kardiotoxicita antracyklínovej lieèby vo svetle nových biochemických diagnostických mo ností D. Urbanová, B. Mladosievičová Ústav patologickej fyziológie, Oddelenie klinickej patofyziológie
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More informationJournal of the American College of Cardiology Vol. 62, No. 14, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 62, No. 14, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.078
More informationESC CONGRESS 2010 Stockholm, august 28 september 1, 2010
ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010 CORONARY ARTERY DISEASE AND NUCLEAR IMAGING: AN UPDATE PERFUSION SCINTIGRAPHY IN HIGH-RISK ASYMPTOMATIC PATIENTS Pasquale Perrone Filardi Federico
More informationÚVOD DO INTERPRETÁCIE KLINICKÝCH ŠTÚDIÍ (2. časť)
ÚVOD DO INTERPRETÁCIE KLINICKÝCH ŠTÚDIÍ (2. časť) Mego Michal 1, Mária Rečková 2 1 Národný onkologický ústav, Bratislava 2 POKO, Poprad Cieľom série článkov, ktoré budú venované klinickým štúdiám je pomôcť
More informationAcute Coronary Syndrome. ACC/AHA 2002 Guidelines
Acute Coronary Syndrome ACC/AHA 2002 Guidelines ACS Unstable Angina Non ST elevation MI ST elevation MI ACS UA and Non STEMI described in these guidelines Management of STEMI described in separate guidelines
More informationDolore Toracico e Livelli di Troponina non Misurabili
Dolore Toracico e Livelli di Troponina non Misurabili Andrea Fabbri Dipartimento di Emergenza Presidio Ospedaliero Morgagni Pierantoni Azienda USL Romagna Forlì andrea.fabbri@auslromagna.it Rapid Exclusion
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationTROPONINS HAVE THEY CHANGED YOUR
TROPONINS HAVE THEY CHANGED YOUR PRACTICE THIS WEEK? Harvey White John Neutze Scholar Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Disclosure
More informationEvaluating Rapid Rule-out of Acute Myocardial Infarction Using a High-Sensitivity Cardiac Troponin I Assay at Presentation
Clinical Chemistry 64:5 820 829 (2018) Proteomics and Protein Markers Evaluating Rapid Rule-out of Acute Myocardial Infarction Using a High-Sensitivity Cardiac Troponin I Assay at Presentation Jaimi Greenslade,
More informationBAROREFLEX SENSITIVITY IN PATIENTS WITH DIABETES MELLITUS AND ESSENTIAL HYPERTENSION: EFFECT OF COMBINED THERAPY
SCRIPTA MEDICA (BRNO) 77 (5 6): 277 282, December 2004 BAROREFLEX SENSITIVITY IN PATIENTS WITH DIABETES MELLITUS AND ESSENTIAL HYPERTENSION: EFFECT OF COMBINED THERAPY SVAČINOVÁ H. 1, SIEGELOVÁ J. 1, FIŠER
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationGUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT
GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT sponsored by TROPONIN OVERVIEW TROPONIN DETECTION IN NORMAL AND DISEASE STATES1 The detection of
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationRazionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta
Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta Giuseppe Musumeci SC Cardiologia Ospedale Santa Croce e Carle Cuneo
More informationHow to read the report
Dear Client, This is your second opinion report. How to read the report 1. Always consult your findings with your doctor. 2. Please bear in mind that the report is based only on the information you provide
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationThe NICE chest pain guideline 1 year on. Jane S Skinner Consultant Community Cardiologist The Newcastle upon Tyne Hospitals NHS Foundation Trust
The NICE chest pain guideline 1 year on Jane S Skinner Consultant Community Cardiologist The Newcastle upon Tyne Hospitals NHS Foundation Trust The Society for Acute Medicine, 5 th International Conference,
More informationOverall Changes of the Universal Myocardial Infarction Definition
Overall Changes of the Universal Myocardial Infarction Definition Professor Kristian Thygesen, FESC, FACC, FAHA Aarhus University Hospital, Aarhus, DK Co-Chairman of The Global MI Task Force Declaration
More informationAndreas Baumbach Bristol Heart Institute Bristol Royal Infirmary. London 27/1/2005
Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary AB London 27/1/2005 Revascularisation in ACS ICTUS MERLIN REACT 4mins 4mins 4mins AB Tony s Comments 15mins ICTUS Comparison of an early
More informationClinical Policy: Cardiac Biomarker Testing for Acute Myocardial Infarction Reference Number: CP.MP.156
Clinical Policy: Reference Number: CP.MP.156 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important regulatory and legal information. Description The
More informationNSTE ACS. Timing of intervention
NSTE ACS Timing of intervention Timing of intervention in NSTE-ACS What do the guidelines tell us? Any need for immediate invasive approach? No mortality benefit with an early invasive approach? Putting
More informationThe clinical performance of the novel POC Minicare ctni-assay. Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden
The clinical performance of the novel POC Minicare ctni-assay Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden Disclosure: Per Venge has received consultancy honoraria
More informationPrednemocničná reperfúzna liečba STEMI: pre lepší spánok intervenčného kardiológa a lepšiu prognózu pacienta
Prednemocničná reperfúzna liečba STEMI: pre lepší spánok intervenčného kardiológa a lepšiu prognózu pacienta Kongres SSUMaMK Vyhne 2017 Prof. MUDr. Vasiľ Hricák, CSc, FESC Národný ústav srdcových a cievnych
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationCRP for the Clinician
CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University
More informationPatient and System Time Delay
Quality Indicators in the Management of ST-elevation Myocardial Infarction Patient and System Time Delay Jacob Thorsted Sorensen, MD, PhD Department of Cardiology Aarhus University Hospital, Denmark Disclosures
More informationWomen and Ischemic Heart Disease Lessons Learned
Women and Ischemic Heart Disease 2017- Lessons Learned Bina Ahmed MD Interventional Cardiology Dartmouth-Hitchcock Medical Center Assistant Professor of Medicine Geisel School of Medicine Lebanon, NH ba@hitchcock.org
More informationPerioperative Infarcts: Epidemiology, predictors and post-op monitoring
Friday Nov 3rd, 2017 1pm Perioperative Infarcts: Epidemiology, predictors and post-op monitoring Dr Carol Chong Geriatrician Northern Health, Epping, Victoria, Australia How I became interested in this
More information